KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Interest Expenses (2017 - 2022)

Historic Interest Expenses for Sarepta Therapeutics (SRPT) over the last 6 years, with Q4 2022 value amounting to $6.7 million.

  • Sarepta Therapeutics' Interest Expenses fell 4008.78% to $6.7 million in Q4 2022 from the same period last year, while for Sep 2023 it was $6.7 million, marking a year-over-year decrease of 8887.65%. This contributed to the annual value of $22.0 million for FY2023, which is 5866.51% down from last year.
  • As of Q4 2022, Sarepta Therapeutics' Interest Expenses stood at $6.7 million, which was down 4008.78% from $14.7 million recorded in Q3 2022.
  • Over the past 5 years, Sarepta Therapeutics' Interest Expenses peaked at $20.6 million during Q3 2021, and registered a low of $6.7 million during Q4 2022.
  • For the 5-year period, Sarepta Therapeutics' Interest Expenses averaged around $12.2 million, with its median value being $12.4 million (2020).
  • In the last 5 years, Sarepta Therapeutics' Interest Expenses skyrocketed by 297358.49% in 2018 and then tumbled by 4040.04% in 2021.
  • Over the past 5 years, Sarepta Therapeutics' Interest Expenses (Quarter) stood at $7.2 million in 2018, then grew by 15.74% to $8.4 million in 2019, then skyrocketed by 123.24% to $18.7 million in 2020, then plummeted by 40.4% to $11.2 million in 2021, then plummeted by 40.09% to $6.7 million in 2022.
  • Its Interest Expenses stands at $6.7 million for Q4 2022, versus $14.7 million for Q3 2022 and $17.0 million for Q2 2022.